1. Introduction {#sec1}
===============

Regulatory T cells (Treg cells) are a key member to maintain self-tolerance and immune homeostasis \[[@B1], [@B2]\]. They play crucial roles in a variety of human diseases, such as autoimmune disease, allergy, chronic infection, and cancers \[[@B3]--[@B6]\]. Treg cells can suppress the immune response of CD4^+^ and CD8^+^ T cells mainly by secretion of inhibitory cytokines such as interleukin (IL)-10 and transforming growth factor-*β* (TGF-*β*) \[[@B7], [@B8]\]. Foxp3 is the most specific marker for CD4^+^ Treg cell development and function \[[@B9]--[@B11]\]. Sakaguchi\'s group confirmed that human CD4^+^Foxp3^+^ Treg cells can be divided into three subsets: CD45RA^+^Foxp3^lo^, CD45RA^−^Foxp3^hi^, and CD45RA^−^Foxp3^lo^ cells \[[@B12]\]. CD4^+^CD45RA^+^Foxp3^lo^ Treg cells as antigen-experienced cells are referred to as resting Treg cells (rTreg) \[[@B13]--[@B15]\]. CD4^+^CD45RA^−^Foxp3^hi^ Treg cells which are activated with highly suppressive function and proliferating ability*in vivo* are defined as activated Treg cells (aTreg) \[[@B13]--[@B15]\]. CD4^+^CD45RA^−^Foxp3^lo^ Treg cells include a remarkable amount of nonregulatory, cytokine-secreting T cells (nonsuppressive T cells or non-Treg cells) \[[@B13]--[@B15]\].

Elevated Treg cells reduce immune responses against tumor and induce excessive tumor progression \[[@B16], [@B17]\]. CD4^+^CD25^+^ Treg cells are augmented in tumor tissue as well as in circulation in patients with malignant melanoma, Hodgkin lymphoma, and lung, gastric, ovarian, pancreatic, and breast cancer \[[@B18]--[@B20]\]. Traditionally, the aim of chemotherapy is direct cytotoxicity to induce tumor cell death. Taxanes containing docetaxel or paclitaxel have been used to treat a variety of malignancies such as lung, prostate, and breast cancers. They have also been reported to modulate components of the immune system in mice by disrupting intracellular microtubular networks \[[@B21]\]. In those studies, docetaxel showed clear antitumor effects and further enhanced antitumor effects by modulation of immune cell subsets or regulatory T cells. However, no study has demonstrated the effect of docetaxel on the frequency and function of individual Treg cell subsets.

In this report, we characterized three subsets of CD4^+^Foxp3^+^ Treg cells in NSCLC patients. Only aTreg cells have been found to increase in NSCLC patients, especially in patients with advanced NSCLC. We also identified the relationship between three Treg subsets and pathological characteristics. Finally, our data demonstrate that docetaxel modulates different subsets of Treg cells both in*in vitro* analysis and*in vivo* clinical settings.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Blood Samples {#sec2.1}
-------------------------------

From February 2013 to November 2013, 40 patients with NSCLC from the First Affiliated Hospital of Zhengzhou University were enrolled. The patients have not been treated with anticancer drugs, radiotherapy, or surgery in the beginning of the study and have no other systemic diseases. Peripheral blood was collected from 40 patients with NSCLC and 20 healthy donors with similar gender and age distribution, respectively. All patients gave written informed consent. The whole consent procedure was in accordance with the standard defined by Institutional Review Boards of the First Affiliated Hospital of Zhengzhou University. Patient characteristics were summarized in [Table 1](#tab1){ref-type="table"}.

2.2. Antibodies and FACS Analysis {#sec2.2}
---------------------------------

Fresh human peripheral blood mononuclear cells (PBMCs) were stained with anti-CD4 (PerCP-Cy 5.5 or APC-Cy7-conjugated from BD Bioscience), anti-CD25 (APC-Cy7 or APC-conjugated from BD Bioscience), and anti-CD45RA (FITC-conjugated from BD Bioscience). Intracellular detection of Foxp3 with anti-Foxp3 (PE-conjugated from BD Bioscience) was performed on fixed and permeabilized cells with the Foxp3 staining buffer set (Biolegend, USA) according to the manufacturer\'s instructions. The following fluorescence-conjugated antibodies were also used: CD39 (APC), Interferon-*γ* (IFN-*γ*) (PE-Cy7 or APC), and TGF-*β* (APC) obtained from BD Biosciences. PBMCs were stained according to the manufacturer\'s recommendations. The appropriate isotype-matched control antibodies were purchased from BD Bioscience. Cells were analyzed using a FACSCantoII flow cytometer (BD, USA) and Diva analysis software (BD, USA).

2.3. Intracellular Staining {#sec2.3}
---------------------------

Intracellular staining for IFN-*γ* and TGF-*β* was performed as follows: PBMCs were freshly isolated and stimulated with 1 mg/mL PMA (Sigma, USA) and 1 mg/mL ionomycin (Sigma, USA) in the presence of Brefeldin-A (BFA, Biolegend, USA) for 5 h. Cells were stained for cell surface markers and then fixed and permeabilized with anti-human Foxp3 Ab for intracellular cytokine staining. FACSCanto II flow cytometer (BD, USA) was used to determine fluorescence intensity and Diva analysis software was used to analyze the data.

2.4. Cell Isolation and Sorting {#sec2.4}
-------------------------------

PBMCs were isolated by density gradient centrifugation (Tianjin HY, China) within 2 h after sample collection. There is a linear correlation between CD25 and Foxp3 levels expressed on CD4^+^CD25^+^ T cells \[[@B7]\]. To isolate live Treg subsets for functional assays, the PBMCs were stained with CD4 and CD25 Abs and sorted using Moflo-XDP (Beckman Coulter, USA) according to the manufacturer\'s instructions. The purity of CD4^+^CD25^+^ T cells was \>90%, confirmed by flow cytometry (data not shown).

2.5. *In Vitro* Assay of Docetaxel Effect on the Treg Subsets {#sec2.5}
-------------------------------------------------------------

The purified CD4^+^CD25^+^ T cells were resuspended in RPMI1640 (Gibco, USA) containing 10% fetal bovine serum (FBS, Sigma, USA), 100 U/mL penicillin, and 100 *μ*g/mL streptomycin. After 24 h of incubation in the atmosphere with 5% CO~2~ at 37°C, 100 IU/mL IL-2 (Beijing SL, China) and 1 *μ*g/mL docetaxel (Zhejiang WM, China) were added. Assay cultures after 36 h were harvested and ready for phenotype and cytokine analysis of the three subsets of Tregs, aTreg, rTreg, and non-Treg cells being, respectively, defined as CD4^+^CD45RA^−^CD25^hi^, CD4^+^CD45RA^+^CD25^lo^, and CD4^+^CD45RA^−^CD25^lo^ T cells.

2.6. Therapeutic Regimen {#sec2.6}
------------------------

Of these 40 NSCLC patients, 17 received cisplatin (75 mg/m^2^) plus docetaxel (30 mg/m^2^ on day 1 and day 8) every three weeks. All patients were treated for 4 cycles.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Differences between groups were assessed using Student\'s *t*-test and paired *t*-test. The correlation between Treg cell subsets and clinical characters was determined by one-way ANOVA. The change of Treg cells treated with docetaxel was determined by randomized block design ANOVA. *P* values were considered significant at *P* \< 0.05 (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001). Statistical analyses were performed in SPSS version 17.0.

3. Results {#sec3}
==========

3.1. Only aTreg Cells Increased in NSCLC Patients {#sec3.1}
-------------------------------------------------

The combination of Foxp3 and CD45RA staining of CD4^+^ T cells in PBMCs of NSCLC patients revealed the existence of three subsets of Treg cells ([Figure 1(a)](#fig1){ref-type="fig"}). Notably, these three CD4^+^Foxp3^+^ populations could be distinctly separated into Foxp3^lo^CD45RA^+^ cells (rTreg cells), Foxp3^hi^CD45RA^−^ cells (aTreg cells), and Foxp3^lo^CD45RA^−^ cells (non-Treg cells). As shown in [Figure 1(b)](#fig1){ref-type="fig"}, the percentage of CD4^+^Foxp3^+^ Treg cells from PBMCs increased in NSCLC patients compared to healthy donors (1.76 ± 0.17% versus 1.01 ± 0.16%, *P* \< 0.01). We further analyzed three subsets of CD4^+^Foxp3^+^ cells in total CD4^+^ T cells. Our data showed that only aTreg cells but not rTreg or non-Treg cells increased in NSCLC patients compared to healthy donors (1.07 ± 0.16% versus 0.25 ± 0.04%, *P* \< 0.001), indicating that aTreg cells might play an important role in the pathogenesis of lung cancer.

3.2. Activated Treg Cells Expressed Higher Levels of CD39 and Inhibitory Cytokines in Patients with NSCLC {#sec3.2}
---------------------------------------------------------------------------------------------------------

To evaluate the suppressive function of Treg subsets, we further detected the phenotypes of different Treg subsets in patients with NSCLC. CD39 is an ectonucleotidase and has been defined as an additional important marker for Treg cells, which converts extracellular ATP into immunosuppressive adenosine \[[@B22]\]. CD39 has been defined as an additional important functional marker for Treg cells \[[@B23]\]. So, CD39 expression was detected in the three Treg cell subsets. We found that CD39 was enriched in aTreg and rTreg cells in comparison to non-Treg cells in PBMCs ([Figure 2(a)](#fig2){ref-type="fig"}). We also studied the cytokine pattern in Treg cell subsets in PBMCs from NSCLC patients after*ex vivo*stimulation. As shown in [Figure 2(b)](#fig2){ref-type="fig"}, aTreg cells secreted significant amount of TGF-*β* (*P* \< 0.05) but very little INF-*γ* (*P* \< 0.001) compared to non-Treg cells. In contrast, non-Treg cells predominantly secreted INF-*γ* but not TGF-*β*. Activated Treg cells also secreted more TGF-*β* than rTreg cells, but the difference is not significant. These characteristics suggest that aTreg cells were the major Treg subset with inhibitory function in NSCLC patients.

3.3. Activated Treg Cells Correlated with Advanced Pathological Stages in NSCLC Patients {#sec3.3}
----------------------------------------------------------------------------------------

The clinical relevance of Treg cell subsets with tumor stages and other pathological factors was examined. In thirty-two NSCLC patients at stages III-IV, the percentage of CD4^+^Foxp3^+^ Treg cells in PBMCs was significantly higher than that in patients at stages I-II (2.01 ± 0.23% versus 0.98 ± 0.25%, *P* \< 0.05, [Figure 3(a)](#fig3){ref-type="fig"}). We also evaluated whether the subsets of Treg cells correlated with tumor stages. The frequency of aTreg cells was much higher in patients with NSCLC at stages III-IV (1.30 ± 0.18% versus 0.38 ± 0.09%, *P* \< 0.05, [Figure 3(a)](#fig3){ref-type="fig"}). However, there were no significant differences in the subsets of Treg cells between different types of histology ([Figure 3(b)](#fig3){ref-type="fig"}).

3.4. Effect of Docetaxel on Three Subsets of Treg Cells {#sec3.4}
-------------------------------------------------------

Previous studies have shown that docetaxel induced tumor cell death and also increased the number of CD4^+^ and CD8^+^ T cells \[[@B24]\]. We investigated if docetaxel had different effects on each Treg subset. To address this issue, we treated purified CD4^+^CD25^+^ T cells derived PBMCs from NSCLC patients with docetaxel*in vitro*. Because the degree of Foxp3 was proportional to CD25 expression ([Figure 4(a)](#fig4){ref-type="fig"}), we isolated and defined aTreg, rTreg, and non-Treg cells as CD4^+^CD45RA^−^CD25^hi^, CD4^+^CD45RA^+^CD25^lo^, and CD4^+^CD45RA^−^CD25^lo^ T cells. Three subsets of Treg cells were all decreased after docetaxel treatment. More interestingly, aTreg cells secreted more INF-*γ* and less TGF-*β* after docetaxel treatment (*P* \< 0.05, [Figure 4(b)](#fig4){ref-type="fig"}). But there were no significant differences for cytokine production in rTreg and non-Treg cells after docetaxel treatment.

To further confirm the clinical effect of docetaxel on Treg subsets, we collected peripheral blood from NSCLC patients 1 day before the first cycle and 2 weeks after each cycle of docetaxel treatment. As shown in [Figure 5](#fig5){ref-type="fig"}, three subsets of Treg cells were reduced after four cycles of chemotherapy (*P* \< 0.05). The trend we observed coincided with the results observed*in vitro*.

4. Discussion {#sec4}
=============

The adaptive immune system plays an important role in control of tumor development. Treg cells increased in most human solid tumors and can suppress antitumor immune responses by inhibition of tumor-specific CD8 T cells \[[@B24]\]. More and more reports showed that the increased number of Treg cells in solid tumors was related to greater tumor progress and poorer survivals \[[@B25]\]. Recently, CD4^+^Foxp3^+^ Tregs in tumor tissue were reported to have significantly increased compared with normal lung tissue \[[@B26]\]. In this study we reported significant increase of aTreg cells in peripheral blood of NSCLC patients. Consistent with previous studies, we confirmed that Treg cells increased in PBMCs. Furthermore, our results characterized three distinct subsets of Treg cells in NSCLC patients and revealed the relationship between Treg subsets and several pathological factors. The conversion of non-Treg cells to Treg cells is one of the mechanisms to promote the accumulation of Treg cells in suppressing antitumor immune response \[[@B27]\]. Activated Treg cells are highly proliferative*in vivo*but rapidly died, and rTreg cells can differentiate to aTreg cells under stimulation. However, we did not detect the translation of rTreg in NSCLS. Our results showed that depleting Treg cells might be therapeutically beneficial for the tumor immunotherapy \[[@B13]\].

Multiple mechanisms have been reported for Treg cells implicating in the immune suppression of human cancer, which may be potential target for depleting Tregs for immunotherapy \[[@B28]\]. In order to explore the potential factors contributing to the conversion in Treg cells, we identified the differences of cytokines and other cell surface makers among three Treg subsets. Autocrine IFN-*γ* was reported to regulate TGF-*β*-driven Foxp3 expression in induced regulatory T cells (iTreg) and suppress the conversion of naïve CD4 T cells into CD4^+^Foxp^+^ T cells \[[@B29]\]. We found lower IFN-*γ* in aTreg cells compared with non-Treg cells, suggesting that aTreg cells produce lower level of IFN-*γ* to suppress the antitumor immune responses. TGF-*β* serves as a pleiotropic regulator of essential functions in immune cells \[[@B30]\]. TGF-*β* signaling pathway can inhibit Tregs proliferation in thymus and promote CD8^+^ T cell maturation as well as NKT cell development \[[@B31]\]. But TGF-*β* is also required for Tregs development and survival. And no response to TGF-*β* can decrease the number of Tregs \[[@B31]--[@B33]\]. In this study, we found higher expression of TGF-*β* in aTreg cells. Among three subsets of Treg cells, aTreg which performed high proliferation, corresponding to HLA-DR-expressing and suppressing the proliferation of responder cells, was the main functional population of Tregs. It has been showed that the TGF-*β* pathway related genes have dysregulation between different Treg cell subsets \[[@B34]\], indicating that the high expression of TGF-*β* in aTreg cells was important for the Treg cells function. The high expression of TGF-*β* can induce a series of molecular events regulation which contributed to cell cycle, apoptosis, and others. Our findings supported the essential role of TGF-*β* for Tregs development and differentiation. CD39 can catalyze the conversion of extracellular ATP or ADP to AMP and act as another key mechanism of Tregs in suppressing antitumor immune response \[[@B35]\]. CD39 expressed on Tregs was reported to inhibit NK activity and promote hepatic metastatic tumor growth \[[@B36]\]. The increased expression of CD39 in CD4^+^ T cells was related to poorer prognosis \[[@B37]\]. We also found high expression of CD39 in aTreg cells from NCSLS patients. Polyoxometalate-1, an inhibitor of nucleoside triphosphate diphosphohydrolase activity, can effectively inhibit the Treg cells activity*in vitro* and the tumor growth*in vivo*\[[@B36]\]. Therefore inhibition of CD39 may promote the antitumor immune responses by suppression of Tregs and act as component of immunotherapy for cancer.

Lung cancer is the most common cause of cancer-related mortality worldwide, with 85% being of the NSCLC histological subtype \[[@B38]\]. Since we found the association of aTregs and the clinical stage of NSCLC, next we detected the portion of Tregs in NSCLC patients after chemotherapies. We found Treg cells decreased after treatment with docetaxel*in vitro*, but only aTreg cells decreased with more IFN-*γ* and less TGF-*β*. We also found that the three subsets of Treg cells were greatly reduced after 4 cycles of chemotherapy. This study of NSCLC patients agreed with our findings*in vitro*. Although the portion of aTregs was extremely lower after 4 cycles of chemotherapy, there are still aTreg and rTregs remaining in peripheral blood. It is already known that rTreg cells can differentiate to aTreg cells after stimulation if aTreg cells die. We considered this may contribute to the recurrence and poor survivals of NSCLC. The depletion of Treg cells can significantly prolong survival in combination with chemotherapy in preliminary studies; on the other hand, chemotherapy can decrease Treg cells to improve antitumor immunity \[[@B26], [@B39]\]. Our results combined with others shed light on the development of new therapeutic schedules combining chemotherapy with immunotherapy.

5. Conclusion {#sec5}
=============

In conclusion, we found that aTreg cells significantly increased in NSCLC patients and associated with late clinical stages. In this study, we also found aTreg significantly decreased after effective chemotherapy. In molecular events, it showed that aTreg cells showed lower levels of IFN-*γ* and higher level of TGF-*β* and CD39. The chemotherapy drug docetaxel can decrease aTreg cells and change the expression of IFN-*γ* and TGF-*β*. This study indicates that the inhibition of TGF-*β* and CD39 to suppress Tregs may act as a component of immunotherapy for cancer. It also provides the potential of combination with chemotherapy and immunotherapy in the future.

The authors thank Ms. Yan Yan and Dr. Wenjie Dong (the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China) who assisted in the collection of blood samples. This study was supported by grants from the National Natural Science Foundation of China (Grant nos. 81171985 and 81171986), Research Grant from the Ministry of Public Health (no. 20110110001), the Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province (Grant no. 112300410153 and Grant no. 122300410155), Funds for Creative Research Team of Henan Province, Creative Research Team of Higher Education of Henan Province, and the Innovation Team of the First Affiliated Hospital of Zhengzhou University.

Conflict of Interests
=====================

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors\' Contribution
======================

Jie-Yao Li and Xiu-Fang Duan contributed equally to this work.

![aTreg but not rTreg and non-Treg cells increased in NSCLC patients. (a) CD4^+^Foxp3^+^ T cells and three subsets of Treg cells from PBMCs were isolated and analyzed by FACS. (b) The percentages of Treg cells (CD4^+^Foxp3^+^ T (total Treg) cells, CD4^+^CD45RA^−^Foxp3^hi^ (aTreg) cells, CD4^+^CD45RA^−^Foxp3^lo^ (non-Treg) cells, and CD4^+^CD45RA^+^Foxp3^lo^ (rTreg) cells) in CD4^+^ T cells were calculated after FACS analysis. HD: healthy donor, *n* = 20; NSCLC: nonsmall cell lung cancer, *n* = 40. Each dot represents one individual sample. \*\**P* \< 0.01 and \*\*\**P* \< 0.001 for statistical analysis by Student\'s *t*-test.](JIR2014-286170.001){#fig1}

![aTreg cells expressed higher immunosuppressive marker CD39 in NSCLC patients and secreted suppressive cytokines. (a) PBMCs were collected from NSCLC patients. The phenotype marker of CD39 was evaluated in the three subsets of CD4^+^Foxp3^+^ Treg cells, including aTreg, non-Treg, and rTreg cells. The dot plots (left) represent the expression of CD39 in each group. The bar figures (right) represent the mean percentage of each population ± standard error of mean. (b) These cells were also stimulated*in vitro* and the cytokine profiles including TGF-*β* and IFN-*γ* were analyzed. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 by paired *t*-test.](JIR2014-286170.002){#fig2}

![aTreg cells had a higher level in patients with advanced NSCLC. NSCLC patients were grouped according to clinical stage and pathology. (a) The percentages of CD4^+^Foxp3^+^ T cells, aTreg cells, non-Treg cells, and rTreg cells were compared in PBMCs of NSCLC patients at stages I-II and III-IV. (b) The 4 groups of Treg cells were compared in PBMCs of NSCLC patients between adenocarcinoma and squamous carcinoma. Statistical analysis was determined by one-way ANOVA. \**P* \< 0.05.](JIR2014-286170.003){#fig3}

![The three Treg subsets reduced after being treated with docetaxel*in vitro*. (a) PBMCs from NSCLC patients were staining with CD25 and Foxp3 antibody and analyzed by flow cytometry. (b) The peripheral blood of NSCLC patients was collected and CD4^+^CD25^+^ T cells were isolated by flow cytometric sorting. Three Treg subsets were defined with CD4^+^CD45RA^−^CD25^hi^ (aTreg) cells, CD4^+^CD45RA^−^CD25^lo^ (non-Treg) cells, and CD4^+^CD45RA^+^CD25^lo^ (rTreg) cells. The differences of three subsets with or without docetaxel were analyzed. \**P* \< 0.05; \*\**P* \< 0.01 by paired *t*-test.](JIR2014-286170.004){#fig4}

![Treg cell subsets of NSCLC patients were decreased after chemotherapy. The patients with NSCLC received 4 cycles of chemotherapy and the peripheral blood was collected 1 day before the first cycle and 2 weeks after each cycle. Three subsets were analyzed by FACS. Statistical analysis was determined by randomized block design ANOVA. \**P* \< 0.05.](JIR2014-286170.005){#fig5}

###### 

Clinical and pathologic characteristics of patients (*n* = 40).

  -----------------------------------------------
  Characteristics   Number of\   Proportion (%)
                    patients     
  ----------------- ------------ ----------------
  Sex               40            

   Male             24           60

   Female           16           40

  Age (years)                     

   \<60             10           25

   ≥60              30           75

  Pathology                       

   Adenocarcinoma   20           50

   Squamous         20           50

  Stage                           

   I-II             8            20

   III-IV           32           80
  -----------------------------------------------
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